Motley Fool Premium
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (TSX: BHC)
    3. /

TSX:BHC (Bausch Health Companies Inc.)

About BHC

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (TSX: BHC) Latest News

    The Motley Fool
    Investing

    3 Soaring Stocks Courting Controversy

    | Benjamin Sinclair

    These names are certainly worth considering, but they don't come without some controversy.

    Read more »

    The Motley Fool
    Investing

    Attention Investors: Don’t Miss Out on This Trillion-Dollar Trend

    | Nelson Smith

    This trend could be the biggest opportunity of our investing lives.

    Read more »

    The Motley Fool
    Investing

    3 Stocks to Avoid in a Market Correction

    | Karen Thomas, MSc, CFA

    Is the market going into a downturn? If so, here are three stocks you shouldn't hold.

    Read more »

    The Motley Fool
    Investing

    Can the TSX Rally Last?

    | Sandra Mergulhão

    Canada’s stock exchange is the second-best-performing market after India, but can it keep going up?

    Read more »

    The Motley Fool
    Investing

    Which Health Care Stock Belongs in Your Portfolio?

    | Benjamin Sinclair

    There isn't much to choose from in Canada, but with an aging population, this may be too good an opportunity…

    Read more »

    The Motley Fool
    Investing

    The Case For and Against Valeant Pharmaceuticals

    | Patrick Li

    Here are three reasons for optimism and three reasons for caution.

    Read more »

    The Motley Fool
    Investing

    2 Stocks to Watch this Week

    | Deon Vernooy, CFA

    BlackBerry and Valeant are in the spotlight this week.

    Read more »

    Investing

    2 Controversial Stocks With High Returns — Are They Worth the Risk?

    | Benjamin Sinclair

    Valeant and CGI Group offer big returns, but there are reasons to be concerned.

    Read more »

    Investing

    Thinking of Buying Valeant? Consider These 2 Stocks Instead

    | Benjamin Sinclair

    These two companies also have a remarkable track record, but aren't quite as polarizing.

    Read more »

    The Motley Fool
    Investing

    Is Valeant’s Big Offer for Allergan Big Enough?

    | Deon Vernooy, CFA

    Or is Valeant set to offer even more?

    Read more »

    The Motley Fool
    Investing

    3 Top Stock Picks From Aurion Capital

    | Benjamin Sinclair

    Aurion Capital's Greg Taylor revealed his favourite stock picks. Which of them should you add to your portfolio?

    Read more »

    The Motley Fool
    Investing

    Allergan Wants Nothing to Do With Valeant’s Stock. Should You?

    | Iain Butler

    Breaking down Valeant-Allergan, potentially Canada's largest-ever acquisition. The most recent edition of Take Stock is here!

    Read more »